According to a commentary, this study is the first publication of the International Pregnancy Safety Study consortium, a collaboration among research groups in multiple countries with access to health care databases. It notes that any study that sheds light on the many unknowns related to prescription medication use during pregnancy is a welcome addition to the literature, particularly when researchers apply appropriately rigorous methods, as in the current study. It adds that while the absolute increase in cardiac malformation risk associated with methylphenidate in the study was small, these results make an important contribution to the question of the safety of methylphenidate and amphetamine use during pregnancy.